ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Closed 08-13 16:00:00 EDT

9.41

-0.37

-3.78%

盘后9.42

+0.01+0.11%

19:34 EDT

High9.87	Low9.24	Vol3.11M
Open9.85	D1 Closing9.78	Amplitude6.39%
Mkt Cap2.11B	Tradable Cap1.98B	Total Shares223.98M
T/O29.30M	T/O Rate1.48%	Tradable Shares210.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":9.41,"timestamp":1786651200000,"preClose":9.78,"halted":0,"volume":3107174,"hourTrading":{"tag":"盘后","latestPrice":9.42,"preClose":9.41,"latestTime":"19:34 EDT","volume":46541,"amount":438054.8158,"timestamp":1786664051171,"change":0.01,"changeRate":0.001063,"amplitude":0.007439},"delay":0,"changeRate":-0.03783231083844573,"floatShares":210508436,"shares":223984700,"eps":0.700352,"marketStatus":"Closed","change":-0.37,"latestTime":"08-13 16:00:00 EDT","open":9.85,"high":9.865,"low":9.24,"amount":29297397.608822,"amplitude":0.063906,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.700352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786694400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.78,"preHourTrading":{"tag":"盘前","latestPrice":9.83,"preClose":9.78,"latestTime":"09:07 EDT","volume":216,"amount":2129.75244,"timestamp":1786626425025,"change":0.05,"changeRate":0.005112,"amplitude":0.107362},"postHourTrading":{"tag":"盘后","latestPrice":9.42,"preClose":9.41,"latestTime":"19:34 EDT","volume":46541,"amount":438054.8158,"timestamp":1786664051171,"change":0.01,"changeRate":0.001063,"amplitude":0.007439},"volumeRatio":1.016884,"impliedVol":0.4431,"impliedVolPercentile":0.1275},"requestUrl":"/m/hq/s/ADMA/tweets","defaultTab":"tweets","newsList":[{"id":"2659130194","title":"Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2659130194","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659130194?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:37","pubTimestamp":1786610237,"startTime":"0","endTime":"0","summary":"ADMA Biologics recently reported its second-quarter 2026 results, with sales of US$124.4 million and net income of US$37.82 million, and it reaffirmed full-year revenue guidance of US$530 million to US$560 million.\nThe combination of higher quarterly and year-to-date earnings per share versus last year and maintained revenue expectations highlights management’s confidence in the company’s current operating trajectory.\nNext, we’ll consider how ADMA’s reaffirmed 2026 revenue guidance could...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/why-adma-biologics-adma-is-up-56-after-reaffirming-2026-reve","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/why-adma-biologics-adma-is-up-56-after-reaffirming-2026-reve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657685045","title":"ADMA Biologics (ADMA) Is Up 6.3% After Faster Net Income Growth Than Sales In Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657685045","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657685045?lang=en_us&edition=fundamental","pubTime":"2026-08-06 15:38","pubTimestamp":1786001889,"startTime":"0","endTime":"0","summary":"ADMA Biologics, Inc. reported its second-quarter 2026 results on August 5, 2026, with sales of US$124.4 million and net income of US$37.82 million, alongside higher basic and diluted earnings per share from continuing operations compared with the same period in 2025.\nAn interesting takeaway is that net income growth for the first half of 2026 outpaced the modest increase in sales, suggesting improved cost efficiency and profitability across ADMA’s plasma-derived biologics operations.\nWe’ll...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-is-up-63-after-faster-net-income-growth","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-is-up-63-after-faster-net-income-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657574713","title":"ADMA Biologics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657574713","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657574713?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:50","pubTimestamp":1785970239,"startTime":"0","endTime":"0","summary":"ADMA Biologics, Inc. reports results for the quarter ended June 30 - Earnings SummaryADMA Biologics, Inc.ADMA.OQreported quarterly adjusted earnings of 16 cents per share for the quarter ended June 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4423V3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657574627","title":"ADMA Biologics Q2 2026 Earnings: ASCENIV Mix Drives Margin Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2657574627","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657574627?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:36","pubTimestamp":1785965773,"startTime":"0","endTime":"0","summary":"ADMA Biologics’ Q2 2026 revenue rose 2% year over year to $124.4 million, while diluted EPS increased to $0.16 from $0.14. ASCENIV revenue grew 23.5% to $102.9 million and pushed gross margin to 69% from 55%, offsetting a 48.5% decline in BIVIGAM revenue. GAAP net income increased 11% to $37.8 million, adjusted EBITDA reached $61.8 million, and first-half operating cash flow improved to $87.8 million. ADMA reiterated its FY2026 guidance despite continued competitive and pricing pressure in the U.S. immune globulin market.","market":"sh","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock11.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock11.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262079835-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657573280","title":"ADMA Biologics Q2 GAAP Net Income Rises 11% to $37.8 Million; Revenue Increases 2% to $124.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657573280","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657573280?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:36","pubTimestamp":1785962175,"startTime":"0","endTime":"0","summary":"ADMA Biologics Q2 GAAP net income rises 11% to $37.8 million; revenue increases 2% to $124.4 millionADMA Biologics posted 2Q 2026 GAAP net income of USD 37.8 million, up 11% year-over-year; GAAP basic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLc1lf68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4585","LU2095319765.USD","IE00BN0W2W23.USD","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BCDF","SG9999014005.SGD","NDAQ","BK4139","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4588","ADMA","SG9999014021.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657207085","title":"ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657207085","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657207085?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:14","pubTimestamp":1785960863,"startTime":"0","endTime":"0","summary":"ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60970673/adma-biologics-q2-adj-eps-0-16-misses-0-17-estimate-sales-124-395m-miss-131-658m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657552709","title":"ADMA Biologics Q2 Net Income USD 37.822 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657552709","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657552709?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:06","pubTimestamp":1785960370,"startTime":"0","endTime":"0","summary":"BRIEF-ADMA Biologics Q2 Net Income USD 37.822 MillionAug 05 (Reuters) - ADMA Biologics outlook FY revenue USD 530-560 million vs. IBES estimate USD 559.5 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXTF4ZK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656307907","title":"ADMA Biologics Inc Expected to Post Earnings of 17 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656307907","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656307907?lang=en_us&edition=fundamental","pubTime":"2026-08-04 05:32","pubTimestamp":1785792724,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc <ADMA.OQ> expected to post earnings of17cents a share - Earnings PreviewADMA Biologics IncADMA.OQADMA.Ois expected to  show a rise in quarterly revenue when it reports  results on A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655815362","title":"Fraud And Revenue-Recognition Lawsuits Could Be A Game Changer For ADMA Biologics (ADMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655815362","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655815362?lang=en_us&edition=fundamental","pubTime":"2026-07-30 03:20","pubTimestamp":1785352856,"startTime":"0","endTime":"0","summary":"In recent weeks, ADMA Biologics has been hit with multiple securities class action lawsuits alleging undisclosed related-party transactions, channel stuffing to inflate revenue, and weaknesses in internal controls, following short-seller research and subsequent stock volatility.\nThese lawsuits focus sharply on how ADMA recognized revenue and distributed its ASCENIV product, putting the company’s prior financial reporting under heightened scrutiny.\nWe’ll now explore how these fraud and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/fraud-and-revenue-recognition-lawsuits-could-be-a-game-chang","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/fraud-and-revenue-recognition-lawsuits-could-be-a-game-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655862381","title":"ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655862381","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655862381?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":"Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July  29, 2026  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335099/33130/en/ADMA-Biologics-to-Report-Second-Quarter-2026-Financial-Results-on-August-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","LU2931357623.SGD","PI","BK4139","LU0274383776.USD","BK4141","LU2089985449.USD","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653353147","title":"3 U.S. Drug Manufacturing Stocks Investors Are Watching As Tariffs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2653353147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653353147?lang=en_us&edition=fundamental","pubTime":"2026-07-22 11:30","pubTimestamp":1784691011,"startTime":"0","endTime":"0","summary":"Tariffs on imported generic drugs are set to rise sharply over the next few years, and that kind of policy shock rarely stays contained to one corner of the market. For investors, the question is which U.S. pharmaceutical and biotech manufacturing stocks might stand to benefit if production shifts closer to home, and which could face new pressures through supply chain or pricing risks. This article looks at how the new tariff path could affect larger domestic drug manufacturers and contract...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/3-us-drug-manufacturing-stocks-investors-are-watching-as-tar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/3-us-drug-manufacturing-stocks-investors-are-watching-as-tar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","ONC","BK4139","ISBC","BK4588","BK4526","BK4007","BLTE","BK4211","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449894","title":"ADMA Biologics is Maintained at Outperform by Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449894?lang=en_us&edition=fundamental","pubTime":"2026-07-16 02:30","pubTimestamp":1784140200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADMA/analyst-ratings(END) Dow Jones NewswiresJuly 15, 2026 14:30 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651009435","title":"ADMA Biologics (ADMA) Puts Growth Narrative To The Test As Fair Value Stays In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2651009435","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651009435?lang=en_us&edition=fundamental","pubTime":"2026-07-15 09:24","pubTimestamp":1784078694,"startTime":"0","endTime":"0","summary":"Adma Biologics (ADMA) drew fresh attention after its stock fell 1.21%, trailing broader indices, as investors looked ahead to an earnings release in which analysts expect higher earnings per share and revenue compared with last year.\nSee our latest analysis for ADMA Biologics.\nAt a share price of $8.87, ADMA Biologics has seen short term momentum soften, with the share price return down over the past week and quarter, while a very large 5 year total shareholder return shows how strong earlier...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-puts-growth-narrative-to-the-test-as-fai","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-puts-growth-narrative-to-the-test-as-fai","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162445915","title":"ADMA Biologics Faces Securities Fraud Class Action Over Channel Stuffing Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=1162445915","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162445915?lang=en_us&edition=fundamental","pubTime":"2026-07-07 03:30","pubTimestamp":1783366221,"startTime":"0","endTime":"0","summary":"Biopharmaceutical firm ADMA Biologics Inc (NASDAQ: ADMA) is confronting a securities fraud class action lawsuit. This follows a report issued by short-seller Culper Research on March 24, 2026, which...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649038621","title":"Exploring 3 High Growth Tech Stocks In The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2649038621","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649038621?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:08","pubTimestamp":1783336135,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen 1.6% and in the past year, it has climbed 19%, with earnings expected to grow by 18% per annum in the coming years. In such a dynamic environment, identifying high growth tech stocks involves looking at companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-cxm/sprinklr/news/exploring-3-high-growth-tech-stocks-in-the-us-market-79","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-cxm/sprinklr/news/exploring-3-high-growth-tech-stocks-in-the-us-market-79","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RUM","ADMA","AIPO","BK7509","CXM","BK4539","BK4077","BK4516","CXM.AU","BK7095","BK4139","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648698591","title":"How Index Inclusion and Legal Scrutiny Will Impact ADMA Biologics (ADMA) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2648698591","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648698591?lang=en_us&edition=fundamental","pubTime":"2026-07-04 02:51","pubTimestamp":1783104716,"startTime":"0","endTime":"0","summary":"In late June 2026, ADMA Biologics was added to the Russell 2000 Defensive and Russell 2000 Growth-Defensive Indexes, broadening its institutional index exposure. \nAt the same time, multiple law firms announced securities class actions alleging channel stuffing and undisclosed related party dealings, putting ADMA’s governance and reporting under legal scrutiny. \nWe’ll now examine how the channel stuffing allegations and related securities lawsuits could reshape ADMA Biologics’ previously...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/how-index-inclusion-and-legal-scrutiny-will-impact-adma-biol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/how-index-inclusion-and-legal-scrutiny-will-impact-adma-biol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","ADMA","ISBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646838471","title":"ADMA Biologics (ADMA) Could Be 51% Undervalued On Securities Fraud Lawsuits","url":"https://stock-news.laohu8.com/highlight/detail?id=2646838471","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646838471?lang=en_us&edition=fundamental","pubTime":"2026-06-26 07:21","pubTimestamp":1782429694,"startTime":"0","endTime":"0","summary":"ADMA Biologics (ADMA) stock is back in focus after multiple law firms filed securities fraud class action lawsuits alleging channel stuffing, undisclosed related party transactions, and misleading statements about internal controls.\nSee our latest analysis for ADMA Biologics.\nAt a recent share price of $8.72, ADMA Biologics has seen short term momentum pick up, with a 1 month share price return of 6.99% and 7 day share price return of 4.93%, even though the year to date share price return is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-could-be-51-undervalued-on-securities-fr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-could-be-51-undervalued-on-securities-fr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645985693","title":"Is Securities Fraud Litigation Over Reported ASCENIV Sales Altering The Investment Case For ADMA Biologics (ADMA)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645985693","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645985693?lang=en_us&edition=fundamental","pubTime":"2026-06-24 02:27","pubTimestamp":1782239271,"startTime":"0","endTime":"0","summary":"In recent months, multiple law firms have filed federal securities class action lawsuits against ADMA Biologics, alleging channel stuffing, undisclosed related-party transactions, and weak internal controls between August 9, 2024 and March 25, 2026.\nThe suits, many prompted by a short-seller report, now center on whether ADMA’s reported ASCENIV revenue and governance practices accurately reflected its true commercial performance.\nWe’ll now examine how these securities fraud allegations and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/is-securities-fraud-litigation-over-reported-asceniv-sales-a","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/is-securities-fraud-litigation-over-reported-asceniv-sales-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643006242","title":"ADMA Biologics Faces Federal Securities Lawsuit Over Alleged Channel Stuffing Scheme and Undisclosed Related Party Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2643006242","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643006242?lang=en_us&edition=fundamental","pubTime":"2026-06-16 01:21","pubTimestamp":1781544061,"startTime":"0","endTime":"0","summary":"ADMA Biologics, Inc. (NASDAQ: ADMA) is facing a federal securities lawsuit after a short seller report and subsequent disclosures allegedly reveale...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/adma-biologics-faces-federal-securities-lawsuit-over-alleged-channel-stuffing-scheme-and-undisclosed-related-party-transactions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/adma-biologics-faces-federal-securities-lawsuit-over-alleged-channel-stuffing-scheme-and-undisclosed-related-party-transactions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["US7Y.BOND","QQQA","NDX","TECS","US10Y.BOND","SQQQ","US12M.BOND",".IXIC","FTEC","TMF","TLTW","ONEQ","ADMA","GPIQ","QDTE","IYW","NVIW.SI","QQQE","US3Y.BOND","QID","QYLG","BK4139","NQmain","JEPQ","TQQQ","US5Y.BOND","PSQ","QQQY","QQQJ","TLT","MNQmain","QQQ","US30Y.BOND","US6M.BOND","TQQY","US2Y.BOND","QQQM","QLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643721211","title":"Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2643721211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643721211?lang=en_us&edition=fundamental","pubTime":"2026-06-13 17:01","pubTimestamp":1781341286,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($NTR) ), ( ($CAVA) ), ( ($CBRL) ), ( ($ADMA) ) and ( ($CRSP) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/nutrien-cava-cracker-barrel-adma-crispr-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/nutrien-cava-cracker-barrel-adma-crispr-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRSP","BK4209","BK4556","BK4588","CAVA","LU1861558580.USD","BK4585","BK4611","BK4139","LU1861559042.SGD","ADMA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0562},{"period":"1month","weight":0.0903},{"period":"3month","weight":0.1506},{"period":"6month","weight":-0.3922},{"period":"1year","weight":-0.4165},{"period":"ytd","weight":-0.4638}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0311},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1331},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.021016},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01871},{"month":3,"riseRate":0.583333,"avgChangeRate":0.064012},{"month":4,"riseRate":0.666667,"avgChangeRate":0.034208},{"month":5,"riseRate":0.583333,"avgChangeRate":0.031016},{"month":6,"riseRate":0.25,"avgChangeRate":-0.047592},{"month":7,"riseRate":0.75,"avgChangeRate":0.097335},{"month":8,"riseRate":0.333333,"avgChangeRate":0.016016},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.032166},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.041559},{"month":11,"riseRate":0.636364,"avgChangeRate":0.093715},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.060542}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction